A Phase 1/2 interventional study of Entecavir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 19 sites in 8 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-05-02.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 42nd largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is the only one in phase 1/2, and was the 10th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 2 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2007, is the only one in phase 1/2, and was the 10th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to determine the appropriate doses of entecavir to use in children and adolescents. Safety, tolerability and efficacy will also be studied
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Entecavir
Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
Also known as: Baraclude, BMS-200475
Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Medical Dictionary for Regulatory Activities (MedDRA) version 16.0 was used.
Time frame: Day 1 to Week 120
Mean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
Cmax and Cmin were derived from plasma concentration of ETV versus time and measured in nanograms per milliliters (ng/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Note: PK parameters were summarized for only Groups A and B. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Time frame: Day 14
Median Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort
Tmax was derived from plasma concentration of ETV versus time and measured in hours (h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Age categories presented below: participants age as of first day of dosing. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Time frame: Day 14
Mean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
Area under the Curve (AUC) was derived from plasma concentration of ETV versus time. AUC(TAU) was calculated by log- and linear trapezoidal summations, TAU = 24 hours, and was measured in nanograms\*hours per milliliter (ng\*h/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Time frame: Day 14
Mean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
CLT/F was calculated by dividing the dose of ETV by AUC(TAU) of ETV and was measured in liters per hour (L/h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
Time frame: At 2 weeks
Number of Participants With HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants
Hepatitis B virus DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS TaqMan - high pure system (HPS) assay and was reported in international units per milliliter (IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline to Week 96
Number of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 96 in Treated Participants
HBeAg loss: HBeAg negative. The method used for the detection of HBe Ag was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline to Week 96
Number of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 96 in Treated Participants
HBsAg loss: HBsAg negative. The method used for detection of HBsAg was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline to Week 96
Number of Participants With Hepatitis B e Antigen Seroconversion Through Week 96 in Treated Participants
HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HB e antibodies (HBeAb), ie both the presence of HBeAb and the absence of HBeAg. The method used for the detection HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline through Week 96
Number of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay at Week 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLD = 6 IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline to Week 96
Number of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay Through Week 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline through Week 96
Number of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 96 in Treated Participants
HB s Ag seroconversion: loss of HBsAg (HBsAg negative) and presence of HB s antibodies (HBsAb). The method used for the detection of HBsAg seroconversion was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline through Week 96
Number of Participants Who Had a Protocol Defined Response (PDR) Through Week 96 in Treated Participants
PDR was defined as confirmed HBV DNA \< 50 IU/mL plus confirmed HBeAg seroconversion on 2 sequential measurements at least 14 days apart. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline to Week 96
Mean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. HBV DNA log10 changes from baseline were summarized over time.
Time frame: Baseline to Week 96
Alanine Aminotransferase (ALT) Normalization From Baseline Through Week 96 in Treated Participants
Normalization in ALT= ALT ≤ 1.0\*upper limit of normal (ULN). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline to Week 96
Number of Participants With HBV DNA by PCR Categories at Weeks 48 and 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
Time frame: Baseline, Week 48, Week 96
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN.
Time frame: Baseline to Week 96
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion was determination of presence of HBeAb and loss of HBeAg. The method used for the detection of HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit.
Time frame: Baseline to Week 96
Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 96 in Treated Participants
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HBeAb. The method used for the detection of HBeAg/Ab serologies was the DiaSorin enzyme immunoassay kit.
Time frame: Baseline to Week 96
Number of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
Toxicity Scale: Division of AIDs (DAIDS) grades Version 1.0. Upper limit of normal (ULN); lower limit of normal (LLN); Cells per Liter (c/L); cells per microliter (c/µL); grams per deciliter (g/dL); milliequivalents per liter (mEq/L); cells per microliter (c/µL): Grade (Gr). Hemoglobin g/dL: Gr1:10.0-10.9;Gr2: 9.0-9.9; Gr3:7.0-8.9; Gr4: \<7.0. International normalization ratio (INR): Gr1:1.1-\<1.5\*ULN; Gr2: 1.6-\<2.0\*ULN; Gr3: 2.1-3.0\*ULN;Gr4: \>3.0\*ULN. Neutrophils/bands c/µL: Gr1;1.0-1.3\*10\^3; Gr2: 0.75-0.99\*10\^3; Gr 3: 0.50-0.749\*10\^3; Gr4: \<0.5\*10\^3.
Time frame: Day 1 to Week 120
Number of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO). Grade (Gr). ALT: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0 \*ULN; Gr3: 5.1-10.0\*ULN; Gr4:\>10.0\*ULN. Aspartate aminotransferase (AST): Gr1: 1.25-\<2.5\*ULN; Gr2:2.6-\<5.0\*ULN; Gr 3: 5.1-10.0\*ULN; Gr4\>10.0\*ULN. Alkaline phosphatase: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0\*ULN; Gr3: 5.1-10.0\*ULN; Gr4: \>10.0\*ULN. Lipase: Gr1:1.1-\<1.5\*ULN;Gr2:1.6-\<3.0\*ULN; Gr3: 3.1-5.0\*ULN; Gr4: \>5.0\*ULN. Creatinine: Gr1: 1.1-1.3\*ULN; Gr2: 1.4-\<1.8\*ULN; Gr3: 1.9 - \<3.4\*ULN; Gr4: \>=3.5\*ULN. Glucose mg/dL (high): Gr1:110-\<125 (Fasting)/116-\<160;Gr2:126-\<250 (F)/161-\<250; Gr3: 251-500; Gr4: \>500.Glucose (low): Gr1: 55-64; Gr2: 40 - \<54; Gr3: 30-39; Gr4: \<30 mg/dL.
Time frame: Day 1 to Week 120
Number of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO) for chloride. Milliequivalents per liter (mEq/L); Grade (Gr). Chloride high (mEq/L): Gr1: 113-\<117; Gr2: 117-\<121; Gr3: 121-125; Gr4: \>125. Potassium low (mEq/L): Gr1: 3.0-3.4; Gr2: 2.5-2.9; Gr3:2.0-\<2.4; Gr4: \<2.0. Potassium high: Gr1; 5.6- \<6.0; Gr2: 6.1-\<6.5; Gr3: 6.6-7.0; Gr4: \>7.0. Sodium high (mEq/L): Gr1; 146-\<150; Gr2: 151-\<154; Gr3: 155-\<159; Gr4: \>=160.
Time frame: Day 1 Week 120
| Milestone | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Started | 35 | 21 | 8 |
| Completed | 24 | 19 | 5 |
| Not completed | 11 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: No longer met criteria | 11 | 2 | 1 |
| Milestone | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Started | 24 | 19 | 5 |
| Completed | 22 | 19 | 5 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Milestone | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Started | 22 | 18 | 5 |
| Completed | 20 | 15 | 3 |
| Not completed | 2 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
Cmax and Cmin were derived from plasma concentration of ETV versus time and measured in nanograms per milliliters (ng/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Note: PK parameters were summarized for only Groups A and B. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
| ng/mL | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) |
|---|---|---|
| Cmax of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3) | 8.07 ± 24 | 16.03 ± 8 |
| Cmax of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7) | 6.29 ± 25 | 19.01 ± 15 |
| Cmax of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9) | 5.11 ± 27 | 11.32 ± 37 |
| Cmin of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3) | 0.244 ± 32 | 0.468 ± 17 |
| Cmin of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7) | 0.320 ± 22 | 0.497 ± 32 |
| Cmin of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9) | 0.271 ± 25 | 0.455 ± 25 |
Tmax was derived from plasma concentration of ETV versus time and measured in hours (h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. Age categories presented below: participants age as of first day of dosing. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
| h | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) |
|---|---|---|
| Tmax of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3) | 0.50 (0.5 to 1.0) | 1.00 (0.5 to 1.5) |
| Tmax of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7) | 0.57 (0.5 to 2.0) | 0.72 (0.5 to 1.0) |
| Tmax of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9) | 0.78 (0.5 to 1.0) | 0.52 (0.5 to 1.0) |
Area under the Curve (AUC) was derived from plasma concentration of ETV versus time. AUC(TAU) was calculated by log- and linear trapezoidal summations, TAU = 24 hours, and was measured in nanograms\*hours per milliliter (ng\*h/mL). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
| ng*h/mL | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) |
|---|---|---|
| AUC(TAU) of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3) | 18.69 ± 21 | 42.26 ± 27 |
| AUC(TAU) of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7) | 20.42 ± 20 | 41.50 ± 21 |
| AUC(TAU) of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9) | 15.96 ± 22 | 35.36 ± 24 |
CLT/F was calculated by dividing the dose of ETV by AUC(TAU) of ETV and was measured in liters per hour (L/h). Blood samples were obtained before study drug administration and at 0.5, 1, 2, 4, 8, and 24 hours after study drug administration on Day 14 (+/- 4 days) for the PK assessment. Plasma samples were analyzed for ETV with a validated method using liquid chromatography-tandem mass spectrometry detection. PK assessment was optional for Group C participants (NA-experienced participants who were included with the September 2011 country-specific protocol amendment). No Group C participants chose to participate in the PK assessment.
| L/h | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) |
|---|---|---|
| CLT/F of ETV (≥ 2 yrs to ≤ 6 yrs), (n=7, 3) | 11.40 ± 2.564 | 12.31 ± 3.102 |
| CLT/F of ETV (> 6 yrs to ≤ 12 yrs), (n=9, 7) | 22.66 ± 6.134 | 21.67 ± 6.940 |
| CLT/F of ETV (> 12 yrs to ≤ 18 yrs), (n=8,9) | 31.92 ± 6.429 | 28.95 ± 6.496 |
Hepatitis B virus DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS TaqMan - high pure system (HPS) assay and was reported in international units per milliliter (IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 1 | 0 | 0 |
| Week 24 | 10 | 3 | 0 |
| Week 36 | 11 | 6 | 0 |
| Week 48 | 14 | 9 | 0 |
| Week 96 | 8 | 11 | 2 |
HBeAg loss: HBeAg negative. The method used for the detection of HBe Ag was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 3 | 0 | 0 |
| Week 24 | 4 | 1 | 0 |
| Week 36 | 5 | 1 | 0 |
| Week 48 | 10 | 3 | 0 |
| Week 96 | 5 | 2 | 0 |
HBsAg loss: HBsAg negative. The method used for detection of HBsAg was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 |
| Week 36 | 1 | 0 | 0 |
| Week 48 | 1 | 0 | 0 |
| Week 96 | 0 | 0 | 0 |
HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HB e antibodies (HBeAb), ie both the presence of HBeAb and the absence of HBeAg. The method used for the detection HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 3 | 0 | 0 |
| Week 24 | 4 | 1 | 0 |
| Week 36 | 5 | 1 | 0 |
| Week 48 | 10 | 3 | 0 |
| Week 96 | 5 | 1 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Medical Dictionary for Regulatory Activities (MedDRA) version 16.0 was used.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Serious Adverse Events (n=24, 19, 5) | 2 | 0 | 0 |
| Discontinuations Due to AEs (n=24,19,5) | 0 | 0 | 0 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLD = 6 IU/mL). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 1 | 0 | 0 |
| Week 24 | 6 | 1 | 0 |
| Week 36 | 7 | 5 | 0 |
| Week 48 | 13 | 6 | 0 |
| Week 96 | 8 | 8 | 1 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 1 | 0 | 0 |
| Week 24 | 9 | 2 | 0 |
| Week 36 | 10 | 5 | 0 |
| Week 48 | 14 | 7 | 0 |
| Week 96 | 8 | 8 | 2 |
HB s Ag seroconversion: loss of HBsAg (HBsAg negative) and presence of HB s antibodies (HBsAb). The method used for the detection of HBsAg seroconversion was the ADVIA Centaur iImmunoassay system. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 |
| Week 24 | 0 | 0 | 0 |
| Week 36 | 0 | 0 | 0 |
| Week 48 | 0 | 0 | 0 |
| Week 96 | 0 | 0 | 0 |
PDR was defined as confirmed HBV DNA \< 50 IU/mL plus confirmed HBeAg seroconversion on 2 sequential measurements at least 14 days apart. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Week 12 | 0 | 0 | 0 |
| Week 24 | 4 | 0 | 0 |
| Week 36 | 4 | 1 | 0 |
| Week 48 | 7 | 3 | 0 |
| Week 96 | 3 | 1 | 0 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. HBV DNA log10 changes from baseline were summarized over time.
| IU/mL | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Week 12 | -4.45 ± 0.2418 | -3.89 ± 0.1592 | -3.80 ± 0.4657 |
| Week 24 | -5.30 ± 0.2744 | -4.85 ± 0.2900 | -3.89 ± 0.5440 |
| Week 36 | -5.61 ± 0.2580 | -5.14 ± 0.2604 | -3.90 ± 0.2499 |
| Week 48 | -5.86 ± 0.2176 | -5.36 ± 0.3032 | -4.32 ± 0.4794 |
| Week 96 | -6.30 ± 0.2576 | -5.86 ± 0.2222 | -5.79 ± 0.5308 |
Normalization in ALT= ALT ≤ 1.0\*upper limit of normal (ULN). Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 1 | 2 |
| Week 4 | 1 | 1 | 2 |
| Week 8 | 3 | 2 | 2 |
| Week 12 | 5 | 7 | 3 |
| Week 18 | 15 | 10 | 5 |
| Week 24 | 15 | 12 | 5 |
| Week 30 | 16 | 13 | 5 |
| Week 36 | 16 | 16 | 5 |
| Week 42 | 16 | 15 | 5 |
| Week 48 | 20 | 18 | 4 |
| Week 96 | 10 | 13 | 3 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. LLQ = 29 IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline >=17,200 IU/mL | 24 | 19 | 5 |
| Week 48: < 50 IU/mL | 14 | 9 | 0 |
| Week 48: 50 - < 172 IU/mL | 1 | 2 | 0 |
| Week 48: 172 - < 1720 IU/mL | 3 | 3 | 1 |
| Week 48: 1720 - < 17,200 IU/mL | 3 | 1 | 3 |
| Week 48: > = 17,200 IU/mL | 1 | 3 | 1 |
| Week 96: < 50 IU/mL | 8 | 11 | 2 |
| Week 96: 50 - < 172 IU/mL | 1 | 1 | 0 |
| Week 96: 172 - < 1720 IU/mL | 3 | 0 | 1 |
| Week 96: 1720 - < 17,200 IU/mL | 0 | 1 | 1 |
| Week 96: > = 17,200 IU/mL | 0 | 0 | 0 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 |
| Week 24 | 10 | 3 | 0 |
| Week 36 | 11 | 4 | 0 |
| Week 48 | 13 | 9 | 0 |
| Week 96 | 7 | 11 | 2 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion was determination of presence of HBeAb and loss of HBeAg. The method used for the detection of HBeAg seroconversion was the DiaSorin - Anti HBe enzyme immunoassay kit.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 |
| Week 24 | 4 | 0 | 0 |
| Week 36 | 4 | 1 | 0 |
| Week 48 | 8 | 3 | 0 |
| Week 96 | 3 | 1 | 0 |
Hepatitis B virus DNA by PCR was measured using the Roche COBAS TaqMan - HPS assay and was reported in IU/mL. Baseline was the last value measured prior to or on the date of the first dose of study therapy. Normalization in ALT= ALT ≤ 1.0\*ULN. HBe seroconversion: loss of HBeAg (HBeAg negative) with positive HBeAb. The method used for the detection of HBeAg/Ab serologies was the DiaSorin enzyme immunoassay kit.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Baseline | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 0 |
| Week 24 | 6 | 3 | 0 |
| Week 36 | 7 | 3 | 0 |
| Week 48 | 5 | 6 | 0 |
| Week 96 | 4 | 10 | 2 |
Toxicity Scale: Division of AIDs (DAIDS) grades Version 1.0. Upper limit of normal (ULN); lower limit of normal (LLN); Cells per Liter (c/L); cells per microliter (c/µL); grams per deciliter (g/dL); milliequivalents per liter (mEq/L); cells per microliter (c/µL): Grade (Gr). Hemoglobin g/dL: Gr1:10.0-10.9;Gr2: 9.0-9.9; Gr3:7.0-8.9; Gr4: \<7.0. International normalization ratio (INR): Gr1:1.1-\<1.5\*ULN; Gr2: 1.6-\<2.0\*ULN; Gr3: 2.1-3.0\*ULN;Gr4: \>3.0\*ULN. Neutrophils/bands c/µL: Gr1;1.0-1.3\*10\^3; Gr2: 0.75-0.99\*10\^3; Gr 3: 0.50-0.749\*10\^3; Gr4: \<0.5\*10\^3.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Hemoglobin | 1 | 0 | 1 |
| International normalization ratio | 4 | 3 | 0 |
| Neutrophils (absolute) + bands | 3 | 3 | 0 |
Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO). Grade (Gr). ALT: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0 \*ULN; Gr3: 5.1-10.0\*ULN; Gr4:\>10.0\*ULN. Aspartate aminotransferase (AST): Gr1: 1.25-\<2.5\*ULN; Gr2:2.6-\<5.0\*ULN; Gr 3: 5.1-10.0\*ULN; Gr4\>10.0\*ULN. Alkaline phosphatase: Gr1:1.25-\<2.5\*ULN; Gr2: 2.6-\<5.0\*ULN; Gr3: 5.1-10.0\*ULN; Gr4: \>10.0\*ULN. Lipase: Gr1:1.1-\<1.5\*ULN;Gr2:1.6-\<3.0\*ULN; Gr3: 3.1-5.0\*ULN; Gr4: \>5.0\*ULN. Creatinine: Gr1: 1.1-1.3\*ULN; Gr2: 1.4-\<1.8\*ULN; Gr3: 1.9 - \<3.4\*ULN; Gr4: \>=3.5\*ULN. Glucose mg/dL (high): Gr1:110-\<125 (Fasting)/116-\<160;Gr2:126-\<250 (F)/161-\<250; Gr3: 251-500; Gr4: \>500.Glucose (low): Gr1: 55-64; Gr2: 40 - \<54; Gr3: 30-39; Gr4: \<30 mg/dL.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| ALT | 23 | 17 | 4 |
| AST | 14 | 9 | 1 |
| Alkaline Phosphatase | 3 | 3 | 0 |
| Lipase | 5 | 12 | 3 |
| Creatinine | 1 | 1 | 0 |
| Glucose, high | 3 | 4 | 1 |
| Glucose, low | 3 | 4 | 1 |
Toxicity Scale: DAIDS Version 1.0 and modified World Health Organization (WHO) for chloride. Milliequivalents per liter (mEq/L); Grade (Gr). Chloride high (mEq/L): Gr1: 113-\<117; Gr2: 117-\<121; Gr3: 121-125; Gr4: \>125. Potassium low (mEq/L): Gr1: 3.0-3.4; Gr2: 2.5-2.9; Gr3:2.0-\<2.4; Gr4: \<2.0. Potassium high: Gr1; 5.6- \<6.0; Gr2: 6.1-\<6.5; Gr3: 6.6-7.0; Gr4: \>7.0. Sodium high (mEq/L): Gr1; 146-\<150; Gr2: 151-\<154; Gr3: 155-\<159; Gr4: \>=160.
| participants | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) |
|---|---|---|---|
| Chloride, high | 3 | 0 | 0 |
| Potassium, low | 1 | 0 | 0 |
| Potassium, high | 1 | 1 | 0 |
| Sodium, high | 4 | 3 | 0 |
Collected over From first dose to date of last dose plus 5 days, up to 120 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A LVD-naive | 0/24 (0%) | 2/24 (8.3%) | 21/24 (87.5%) |
| Group B LVD-exp | 0/19 (0%) | 0/19 (0%) | 17/19 (89.5%) |
| Group C NA-exp | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Event | Group A LVD-naive | Group B LVD-exp | Group C NA-exp |
|---|---|---|---|
| GastroenteritisInfections and infestations | 1/24 | 0/19 | 0/5 |
| PneumoniaInfections and infestations | 1/24 | 0/19 | 0/5 |
| Alanine aminotransferase increasedInvestigations | 1/24 | 0/19 | 0/5 |
| Aspartate aminotransferase increasedInvestigations | 1/24 | 0/19 | 0/5 |
| Event | Group A LVD-naive | Group B LVD-exp | Group C NA-exp |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 4/24 | 9/19 | 1/5 |
| PyrexiaGeneral disorders | 10/24 | 5/19 | 1/5 |
| Upper respiratory tract infectionInfections and infestations | 10/24 | 3/19 | 2/5 |
| HeadacheNervous system disorders | 7/24 | 5/19 | 0/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/24 | 5/19 | 1/5 |
| Abdominal painGastrointestinal disorders | 4/24 | 4/19 | 1/5 |
| VomitingGastrointestinal disorders | 2/24 | 4/19 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 5/24 | 3/19 | 1/5 |
| TinnitusEar and labyrinth disorders | 0/24 | 0/19 | 1/5 |
| Ocular hyperaemiaEye disorders | 0/24 | 0/19 | 1/5 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| Mean | 9.2 ± 5.41 | 11.0 ± 4.42 | 8.8 ± 5.02 | 9.9 ± 4.98 |
| Age, Customized(participants) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| ≥ 2 years to ≤ 6 years | 7 | 3 | 2 | 12 |
| >6 years to ≤ 12 years | 9 | 7 | 2 | 18 |
| >12 years to ≤18 years | 8 | 9 | 1 | 18 |
| Sex: Female, Male(Participants) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| Female | 14 | 7 | 2 | 23 |
| Male | 10 | 12 | 3 | 25 |
| Race (NIH/OMB)(Participants) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 17 | 10 | 5 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 5 | 6 | 0 | 11 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| United States | 10 | 5 | 1 | 16 |
| Taiwan | 3 | 0 | 0 | 3 |
| Canada | 1 | 0 | 0 | 1 |
| Argentina | 3 | 0 | 0 | 3 |
| Belgium | 1 | 1 | 0 | 2 |
| Brazil | 1 | 3 | 0 | 4 |
| United Kingdom | 2 | 1 | 0 | 3 |
| Korea, Republic of | 3 | 9 | 4 | 16 |
| Hepatitis B virus (HBV) deoxyribonucleic acid (DNA)(log10 IU/mL) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| Mean | 7.92 ± 0.864 | 7.74 ± 0.856 | 7.96 ± 0.238 | 7.85 ± 0.812 |
| Alanine Aminotransferase (ALT)(U/L) | Lamivudine (LVD)-Naive (Group A) | Lamivudine (LVD)-Experienced (Group B) | Nucleoside/Tide Analog (NA) - Experienced (Group C) | Total |
|---|---|---|---|---|
| Mean | 142.8 ± 85.18 | 125.7 ± 67.96 | 44.6 ± 22.96 | 125.8 ± 78.83 |
Ran from Jun 2007 to primary completion in Aug 2013, 74 months.
Results were first posted in Aug 2014, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir